All In Biotech

Free tool

FAERS Monitor: Adreview

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022290 or its brand name (Adreview, Iobenguane Sulfate I-123). Reports on generic versions are filed under their own applications.

Reports

114

Serious

64

56% of reports

Hospitalization

13

Death reported

6

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • no adverse event41
  • neutropenia22
  • drug ineffective21
  • radioisotope scan abnormal20
  • mucosal inflammation14
  • fatigue5
  • febrile neutropenia5
  • neuroblastoma recurrent5
  • product use issue4
  • pyrexia4
  • therapy partial responder4
  • vomiting4
  • false positive investigation result3
  • myelodysplastic syndrome3
  • therapy non-responder3

Reports by year received

View as table
YearReports
20101
20134
20143
20156
201610
201714
20183
20194
20209
20215
202221
202311
202412
20254
20267

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,045 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
radioisotope scan abnormalSignal205376.63586.399,295
neuroblastoma recurrentSignal54663.81957.118,414
false positive investigation resultSignal3550.2179.81,138
mucosal inflammationSignal1498.760.41,259
therapy partial responderSignal447.318.1138
no adverse eventSignal4141.832.71,604
myelodysplastic syndromeSignal338.312.575
neutropeniaSignal2229.920.5589
febrile neutropeniaSignal513.95.948
therapy non-responderSignal312.34.021
product use issueSignal43.91.56
drug ineffectiveSignal212.92.027
pyrexia42.10.81
vomiting41.60.60
fatigue51.20.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.